MSD
Clinical Trials
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumours who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
NATIONAL TRIAL REFERENCE NUMBER
NCT02628067
EudraCT
2015-002067-41
EU CT
2022-500397-34-00
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Advanced Solid Tumours, Advanced Solid Tumours, Mesothelioma, Parotid Gland Cancer, Salivary Cancer, Salivary Gland Cancer, Salivary Gland Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Solid Tumors, Solid Tumour, Thyroid Cancer, Thyroid Carcinoma, Vulvar Carcinoma
Age Range
18+
Sex
All
Trial Phase
Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.
Trial start and end dates
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
If you are considering joining a clinical trial, first learn as much as you can about:
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about